An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)
Status:
Completed
Trial end date:
2020-08-31
Target enrollment:
Participant gender:
Summary
An open label exploratory study designed to evaluate the safety, efficacy, and
pharmacokinetics of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin
receptor type 2 biased agonist) in subjects with acromegaly that are treated with
somatostatin analogue (SSA) based treatment regimens.